Skip to main content

Table 1 Percentage of cytotoxicity found in each group and positive (CTR +) and negative (CTR−) controls as determined by quantification of DNA released to the culture medium (DNA) and WST1 metabolic function after 24 h and 48 h of ex vivo follow-up

From: Generation of a novel human dermal substitute functionalized with antibiotic-loaded nanostructured lipid carriers (NLCs) with antimicrobial properties for tissue engineering

 

FSS-AMK 10

FSS-AMK 100

FSS-AMK300

FSS-AMK 1000

FSS-SCM 10

FSS-SCM 100

FSS-SCM300

FSS-SCM 1000

FSS-CTR 10

FSS-CTR 100

FSS-CTR300

FSS-CTR 1000

CTR + 

CTR-

DNA

 24 h

0 ± 0a

0 ± 0a

0 ± 0a

3.7 ± 0.3a,b

0 ± 0a

0 ± 0a

1.1 ± 0.1a,b

0.7 ± 0.2a,b

0 ± 0a

0 ± 0a

0 ± 0a

0 ± 0a

0 ± 0.2a

100 ± 0.5b

 48 h

0 ± 0a

0 ± 0a

0 ± 0a

4.7 ± 1a,b

8.7 ± 1.1a,b

0 ± 0a

0 ± 0a

6 ± 0.8a,b

0 ± 0.1a

0 ± 0a

0 ± 0a

1 ± 2.3a,b

0 ± 0.1a

100 ± 9.2b

WST1

 24 h

14.6 ± 7.1a,b

8.4 ± 3.7a,b

3.7 ± 5.5a,b

0 ± 0a

8.7 ± 8.2a,b

5.8 ± 5.3a,b

0 ± 0a

0 ± 0a

4.6 ± 3.8a,b

10.4 ± 9.2a,b

6.1 ± 3a,b

3.6 ± 3.9a,b

0 ± 5.6a

100 ± 0.1b

 48 h

11.1 ± 10.7a

0.2 ± 0.6a

9.2 ± 3.6a

3 ± 3.7a

5.9 ± 5.7a

2.5 ± 2.6a

0 ± 0a

0 ± 0a

3.4 ± 4.4a

7.7 ± 7.3a

1.4 ± 2.7a

0 ± 0a

0 ± 19.1a

100 ± 0.1b

  1. aDifferences with negative controls are statistically significant
  2. bDifferences with positive controls are statistically significant. FSS: functionalized human dermal skin substitutes containing different types of NLCs (AMK, SCM or CTR) at different concentrations (10, 100, 300 or 1000 µg/ml)